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Abstract
Airway infection leads to progressive damage of the lungs in patients with cystic
fibrosis (CF). Oxidative stress has been implicated as a causative factor in the aetiology
of that process. Supplementation with antioxidant micronutrients (vitamin E, vitamin
C, ß-carotene and selenium), docosahexaenoic acid or glutathione might therefore be
helpful in maintaining an adequate redox balance. Current literature suggests a
relationship between oxidative status and lung function. In this chapter we will
summarize the main pathways of oxidative stress, focusing on results of new
antioxidant treatments.
Keywords: Oxidative stress, fat-soluble vitamins, β-carotene, glutathione, essential
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1. Introduction
1.1. Oxidative stress pathways in cystic fibrosis
Colonization of the respiratory tract by bacterial pathogens in the mucus of CF patients leads
to a sustained inflammatory response characterized by massive influx of polymorphonuclear
neutrophils and the activation of macrophages, eosinophils, monocytes and lymphocytes. An
integral part of this inflammation is the production and release of free radicals such as
superoxide (O2-) and hydroxide (OH-), which can induce oxidative stress. In fact, elevated
levels of proinflammatory cytokines, especially interleukins (IL-1β, IL-6, IL-8), tumour necrosis
factor-α and potent neutrophil chemoattractants found in bronchoalveolar lavage, are
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involved in the production of pro-oxidants leading to apoptosis and tissular damage. Con‐
versely, the production of immunosuppressive cytokine IL-10 with anti-inflammatory
properties is reduced or even suppressed [1].
Thus, the severe and recurrent respiratory inflammation ultimately leads to excessive activated
neutrophils and macrophages, which contribute to the generation of free radicals. Further‐
more, defects in the Cystic Fibrosis Transmembrane Regulator (CFTR) can directly affect
transport and glutathione homeostasis, while maldigestion and malabsorption related to
exocrine pancreatic insufficiency impair the absorption of fat-soluble vitamins and antioxi‐
dants. It has been suggested that the chloride channel CFTR also regulates glutathione,
disturbing the balance between pro- and anti-oxidants and promoting oxidative stress, which
may play an important role in Cystic Fibrosis Related Diabetes, a serious complication
associated with a dramatic increase in morbidity and mortality [2].
Although the cause of CF is well established, the pathogenesis of this progressive multisyste‐
mic disease is not yet fully understood. In fact, the broad spectrum of phenotypes and severity
in CF patients that carry the same combination of mutations suggests additional environmental
or genetic factors.
The CFTR dysfunction in the pancreas causes exocrine pancreatic insufficiency in almost 90%
of patients with CF. This leads to fat malabsorption, which explains the difficulty to gain or at
least maintain weight, and the high incidence of fat-soluble-vitamins and antioxidant (vita‐
mins A, E, and D and carotenoids) deficiency, and also essential-fatty-acids deficiency.
Obviously, the reduced availability of dietary antioxidants may further increase oxidative
stress in CF patients, which apparently plays an important role in multiorgan pathophysiology
of CF.
Consequently, the products of lipid peroxidation, which are markers of oxidative stress, have
been detected in exhaled breath condensate, as well as in blood and urine of CF patients. Thus
products of lipid peroxidation are unstable molecules that can reach distant sites to exert
various effects, including activation of the fibroblast cells in the presence of inflammation,
which further increases oxidative stress [3].
2. Management of oxidative stress in cystic fibrosis
Nutrition plays an essential role in the survival and quality of life of CF patients. CF patients
have high caloric requirements due to an increased resting energy expenditure (REE), bacterial
infection, and malabsorption. REE is higher in CF patients with a more severe phenotype. Lung
function and nutritional status are closely correlated, and the severe weight loss can lead to a
decrease in lean body mass, with consequences for respiratory muscles. There is a significant
correlation between growth retardation and the severity of pulmonary involvement [4].
Recently, Yen et al. found that greater weight at age four years is associated with greater height,
better pulmonary function, fewer complications of CF, and better survival through the age of
18 years. Furthermore, greater weight for age in the peripubertal period is associated, on
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average, with improved tempo and timing of pubertal height growth [5]. Long-term nutritional
management is as integral a part of modern care as pulmonary therapy, and is intimately linked
to pulmonary outcomes.
Dietetic management is based on the replacement of pancreatic enzymes and fat-soluble
vitamins (A, D, E, K), together with a high-protein diet and high calorie intake (120–125% of
the normal recommended daily allowance). The recommended Body Mass Index (BMI) for
adult CF patients is ≥22 kg/m2 for females and ≥23 kg/m2 for males. Overnight enteral nutrition
via nasogastric tube or gastrostomy provides supplementary nutritional support when BMI is
suboptimal [6].
a. Docosahexaenoic acid (DHA)
Essential fatty acid (EFA) imbalance has been identified in CF patients and is characterized by
a decrease in docosahexaenoic acid (DHA) and linoleic acid and an increase in arachidonic
acid (AA) [7]. These characteristics were mainly attributed to intestinal malabsorption due to
exocrine pancreatic insufficiency. In the last few years, new mechanisms have been proposed,
such as intensification of the b-oxidation of polyunsaturated fatty acids (PUFAs), inadequate
dietary EFA consumption, the possibility of an intrinsically defective EFA metabolism in CF
epithelial cells, an increase in the production of proinflammatory eicosanoids, a rise in the
peroxidation of PUFAs, and finally an impairment of desaturases or hepatic lipase activity [8].
It has been observed that long-term intake of the daily mixtures of fatty acids (eicosapentae‐
noic, docosahexaenoic, linoleic and γ-linolenic acid) at a low dose has a positive effect on lung
function and inflammation in adult CF patients. The total number of exacerbations after a year
of supplementation was reduced, while the lean-body-mass and lung-function parameters
measured by spirometry were increased. In addition, supplementation led to improved
parameters of oxidation, inflammation (IgG and IgM) and other clinical parameters [9]. 8-
isoprostane, a free-radical product of lipid peroxidation which is a consequence of oxidative
stress, appears to be a prognostic factor in deterioration of lung function in a short time in
patients infected with Burkholderia cenocepacia. The measured concentration of 8-isoprostane
in exhaled breath condensate of 24 patients did not show any significant relationship with the
clinical parameters during a one- and three-year study [10].
Forty-three CF patients were enrolled in a randomized double-blind placebo-controlled study
with three fatty-acid blends containing mainly n-3 or n-6 FA, or saturated fatty acid acting as
placebo [11]. After three months, in the omega-3 fatty-acid-supplemented group, a significant
decrease in the inflammatory markers, erythrocyte sedimentation rate and IL-8 was reported.
Another, longer-term study (17 participants) demonstrated a significant increase in essential-
fatty-acid content in neutrophil membranes and a significant decrease in the leukotriene B4 to
leukotriene B5 ratio in participants taking omega-3 supplements compared to the placebo [12].
b. Fat-soluble vitamins
Supplementation of CF patients with vitamin E and β-carotene has been effective in preventing
oxidative lung damage [13], as seen by a decrease in lipid peroxidation products. It is believed
that these antioxidants have an important role in maintaining or restoring essential-fatty-acid
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status by protecting polyunsaturated fatty acid from oxidative degradation, as their supple‐
mentation augments levels of plasma polyunsaturated fatty acid.
Carotenoids
Levels of plasma carotenoids such as β-carotene, β-cryptoxanthin, and total lycopene are
significantly lowered in CF patients and this has been associated with higher susceptibility to
lipid peroxidation. Rust et al. [14] examined the effect of long-term oral β-carotene supple‐
mentation in patients with CF. Patients of the CF supplementation group received 1 mg β-
carotene/kg body weight/day (maximally 50 mg β-carotene/day). During high-dose treatment,
a significant decrease in the MDA level and a correction of total antioxidative capacity was
observed.
Renner et al. reported distinct clinical benefits from high-dose (1 mg/kg body weight/ day,
maximum 50 mg/day) supplements. Their patients required significantly fewer antibiotics
during the phase of high-dose β-carotene supplementation and showed a decrease in pulmo‐
nary exacerbations [15]. Lepage et al. reported that the two-month supplementation of CF
patients with 4.42 mg β-carotene, three times per day, led to the normalization of increased
MDA level and increased plasma β-carotene from 0.08 ± 0.03 to 3.99 ± 0.92 μM [16].
At the same time, toxicity issues have been raised for supplementation with water- miscible
vitamin A formulations in CF patients, which may increase serum retinol and possible risk of
CF-associated liver and bone complications [17]. However, β-carotene supplementation seems
to be safe since it does not affect serum concentrations of other carotenoides and retinol [14].
Recent studies have analysed the use and safety of a new CF polyvitamin (AquADEKs ®),
which comprises almost 90% vitamin A in retinol form. Patients on AquADEKs ® maintained
a high level of serum β-carotene, but serum retinol was not above the normal levels. β-carotene
levels were associated with lung function and better nutritional status [18,19], while lipid
peroxidation markers were not affected [20].
Vitamin E (α-tocopherol)
α-tocopherol acts as a membrane antioxidant closely associated with polyunsaturated fatty
acids. Vitamin E’s antioxidative properties might be helpful in reducing the negative effects
of free radicals. Current recommended supplementation of vitamin E in CF patients only
includes α-tocopherol. Supplementation with high levels of α-tocopherol alone may result in
further imbalances in CF patients: such supplementation has been shown to deplete γ-
tocopherol in the blood and tissues [21]. Papas et al. [16] evaluated vitamin E supplementation
with mixed tocopherols. The increase in the blood of levels of γ-tocopherol may be particularly
important for CF patients due to its function as a scavenger of reactive nitrogen species and
its synergistic effects with α-tocopherol [22]. Cystic fibrosis is characterized by neutrophil-
dominated airway inflammation. Activated neutrophils release oxidants, proteases, and
cytokines, further sustaining and increasing the inflammatory response and causing direct
injury to the lungs. Improved antioxidant capacity with γ-tocopherol, especially if present in
the lungs, could potentially decrease oxidant-mediated damage and limit the cytokine-
mediated neutrophil recruitment. It has also been reported that reduced serum levels of
vitamin E are associated with an increased rate of pulmonary exacerbations in CF [23].
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c. Other vitamins and micronutrients
Vitamin C
Vitamin C is present in the respiratory lining fluid of human lungs, and local deficit occurs
during oxidative stress. Experimental findings confirm that vitamin C induced the openings
of CFTR Cl− channels without a detectable increase in intracellular cyclic AMP levels. Vitamin
C instilled into the nasal epithelium of human subjects effectively activates Cl− transport, too.
The pool of vitamin C in the respiratory tract represents a potential nutraceutical and phar‐
maceutical target for the complementary treatment of oxidative stress in patients with CF [24].
In a study by Winklhofer-Roob et al. [25] on 122 children and young adults with CF, ascorbic-
acid concentrations decreased with age, and low vitamin C levels were associated with the
highest indexes of inflammation, so the authors concluded that ascorbic acid could interact
with an inflammation-amplifying circle of activation of alveolar neutrophils and macrophages.
Water-soluble vitamins seem to be well absorbed by patients with CF, but there is documented
evidence of poor dietary intake. A supplement of at least 50–100 mg vitamin C/day should be
prescribed for patients with an unbalanced diet, or if there is evidence of deficiency.
Selenium
Dietary intake of selenium is inversely related to inflammatory markers such as sialic acid and
triacylglycerol [26]. Moreover, a possible role of selenium in the modulation of serum com‐
plement 3, which may be an early marker of metabolic syndrome manifestations, has also been
documented.
Wood et al. carried out an eight-week, double-blind, randomized intervention trial, providing
two groups of patients with low- and high-dose vitamin supplements (500 μg vitamin A and
10 mg vitamin E vs. 500 μg vitamin A, 25 mg β-carotene, 200 mg vitamin E, 300 mg vitamin C
and 90 μg selenium). They demonstrated significant improvement of clinical indicators after
treatment. Increased serum β-carotene, selenium, and fatty-acid concentrations were linked
to improved lung function [27].
Consensus regarding supplementation of antioxidants in CF to include selenium is yet to be
established. Two studies have attempted to demonstrate successfully how the administration
of 2.8 μg/kg/day and 90 μg/day of selenium can decrease oxidative stress in CF [28].
d. Glutathione and n-acetylcysteine
The discovery that CF is associated with significantly diminished efflux of reduced glutathione
(GSH) from most cells in the body [29] offers a new perspective on the pathophysiology of this
disease. GSH plays several important roles; among the most important are the following: 1)
primary water-soluble antioxidant; 2) mucolytic capable of cleaving disulphide bonds; and 3)
regulator of immune-system function [30].
The relationship between redox ratio (GSH:GSSG) and total glutathione (GSH+GSSG) and the
initiation of inflammation is well established [29,30]. GSH is also an important component of
the epithelial lining fluid of the intestines, helping to keep intestinal mucus thin, serving to
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defend the intestinal system against reactive oxygen species, and keeping inflammation in
check under normal circumstances [31].
In a recent placebo-controlled, randomized, double-blinded, clinical trial in 44 paediatric CF
patients aged between 18 months and 10 years [32], treatment with oral glutathione (65 
mg/kg/day) increased weight and BMI z score and improved measures of gut inflammation
(faecal calprotectin) over the course of six months, without adverse side effects. The authors
therefore concluded that Oral GSH might primarily be beneficial in those children with more
severe inflammation of the gut, and suggested that early intervention with oral glutathione in
young CF children with growth failure could forestall decline in pulmonary function in later
years.
Several studies have investigated the potential therapeutic role of inhaled GSH in patients with
CF. Three short-term clinical trials, including a placebo-controlled one, have shown the
tolerability and efficacy of inhaled GSH on pulmonary function in these subjects [33-34]. A
recent 12-month randomized single-blind placebo-controlled trial demonstrated the efficacy
of inhaled GSH (600 mg twice daily) on lung function in CF adults [35]. Three months of
therapy with inhaled GSH resulted in a statistically significant improvement in percentage-
predicted FEV1, measured as a pre-post difference from baseline values, when compared to
the placebo, which persisted at six and nine but not at 12 months. A reduced compliance with
therapy in adult patients could explain the decrease in FEV1 values registered in the last visit.
The best improvements in functional parameters were registered in the subgroup of patients
with moderate lung disease (FEV1 below 81%). These results are in concordance with those
reported by Griese et al. [36], who showed a significant increase of FEV1 absolute values (but
not when expressed as percentage-predicted) from the baseline after three months of GSH
therapy.
N-acetylcysteine (NAC), a well-known cysteine donor for the synthesis of glutathione, has
been used in different diseases to treat GSH deficiency [37]. High-dose oral NAC has been
shown to increase neutrophil GSH levels, decrease airway neutrophil recruitment and reduce
neutrophilic release of airway elastase in CF patients [38]. Skov et al. demonstrated that high-
dose oral NAC (1200 mg x 2/day for 30 days) in CF patients with chronic P. Aeruginosa infection
decreased the level of oxidized vitamin C [39].
Indications of a positive effect of NAC treatment on the lung function of a subgroup of CF
patients have previously been published [40]. Recently, a placebo-controlled randomized
clinical trial (70 CF patients) was conducted in the USA to study the effect of oral NAC on lung
inflammation (ClinicalTrials.gov Identifier: NCT00809094). Oral NAC was administered in a
dose of 1800 mg/day divided into two dosages over a period of 24 weeks and the effects on
the sputum levels of human neutrophil elastase (HNE) were assessed as a primary end-point.
While no statistical significant difference was found between the two groups with regard to
the primary end-point, an improvement in the predicted FEV1% was observed in the NAC-
treated group.
A recent Cochrane review on the use of thiol derivatives, such as NAC, did not find sufficient
evidence to recommend the use of these compounds in the management of CF lung disease,
but concluded that further studies were warranted [41].
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γ-Glutamylcysteine ethyl ester (GCEE) is another potentially interesting GSH pro-drug, which
has proved to have some efficacy in the amelioration of oxidative stress, e.g., in experimental
myocardial infarction [42] and central-nervous-system conditions (see, e.g., [43]). However,
GCEE has not been investigated in CF yet.
New CFTR modulation therapies are being designed to correct the function of the defective
protein (CFTR) made by the CF gene, allowing chloride and sodium to move properly in and
out of cells lining the lungs and other organs. N6022 is a new injectable compound that
modulates the function of the defective CFTR protein and decreases inflammation in the lung.
N6022 is the first of a new class of compounds that increase levels of an important signalling
molecule in the body called S-nitrosoglutathione, or GSNO. These novel compounds have been
shown in preliminary results (Phase 1b trial) to increase the amount of CFTR that reaches the
cell membrane and to stabilize CFTR so that its function can be improved.
3. Conclusion
In conclusion, there appears to be conflicting evidence regarding the clinical effectiveness of
antioxidant supplementation in CF patients. Based on the available evidence, glutathione
(administered either orally or by inhalation) and high doses of β-carotene appear to improve
lung function in some cases and decrease oxidative stress. Further studies, especially in very
young patients, examining clinically relevant outcomes, dose levels and other promising
therapies like CFTR modulation, are necessary before a firm conclusion can be made regarding
the effects on oxidative stress in these patients.
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